Andrew Hore – Quoted Micro 28 December 2020

AQUIS STOCK EXCHANGE TruSpine Technologies (TSP) has delayed the application for FDA approval of its Cervi-LOK spinal device for up to three months. This is due to a lack of testing time because of Covid-19. Computer modelling has enabled the company to make minor modifications, which widens the market for the device. A £250,000 cash […]

Andrew Hore – Quoted Micro 14 December 2020

AQUIS STOCK EXCHANGE Incanthera (INC) says that study results for Sol, a sun cream that prevents skin cancer, have been better than expected. There is significantly greater dermal delivery by Sol compared with four rival products and it was found to be a non-irritant. The cream exceeds bioequivalence compared with oral treatments. A new patent […]

Andrew Hore – Quoted Micro 6 August 2018

NEX EXCHANGE         Veni Vidi Vici Ltd (VVV) joined NEX on 2 August. The minerals investment company has net cash of £513,000, following a £490,000 subscription at 50p a share. The focus will be precious metals and base metals opportunities in Australia, Western Europe and North America. Management will concentrate on capital appreciation. EPE Special […]